About the Event

Our monthly series is an opportunity for representatives from across the MTP sector to connect, collaborate and learn about upcoming opportunities, and hear the stories and successes of WA organisations developing health and medical innovations. Join us over light refreshments each month at the Harry Perkins Institute of Medical Research.

This month’s event will feature insights from Dr Olga Shimoni from Alcolizer Technology. Hear as Dr Shimoni discusses the organisation’s road to global-scale commercialisation, and the pivot to COVID-19 diagnostics.

Details

Thursday 27 April 2023, from 3:30-5:00pm AWST

Ground Floor Auditorium at Harry Perkins Institute of Medical Research, 6 Verdun Street Nedlands.

Agenda

3:30pm Informal networking (COVID restrictions permitting) at ground floor of the Perkins Institute with light refreshments

4:00pm Guided fireside chat

5:00pm Event close

This month's event features Alcolizer Technology.

About Alcolizer Technology

Alcolizer Technology is a world-leader in the field of Alcohol and other Drugs (AOD) testing and has been one of the world’s leading manufacturers of alcohol breath testing equipment for over 25 years, servicing law enforcement agencies, industry and personal users.

In 2021, Alciolizer was one of six companies to share in funding under the Government’s $30 million Commercialisation Fund, which brings together industry and researchers on job-creating projects. Alcolizer’s project focused on a new medical device called the ‘Virulizer’ in partnership with the University of Sydney. The device is a mass market saliva-based antigen test designed to detect COVID-19 in asymptomatic and symptomatic patients within 15 minutes.

About our speaker – Dr Olga Shimoni

Dr Olga Shimoni is a Senior Scientist at Alcolizer Technology, leading R&D into a novel diagnostic test for infectious diseases.

Before moving to the industry, Dr Shimoni held the position of A/Professor and group leader at the University of Technology Sydney (UTS), focusing on translating innovative nanoparticle technologies into mature healthcare products, such as biosensors and in vitro diagnostics. During her academic career, A/Prof Shimoni has co-authored more than 40 research papers in high-impact journals, two book chapters and 2 patents. She actively engaged with industry partners and MedTech start-up communities to commercialise research and has been involved in establishing a start-up. Furthermore, she has successfully attracted over $5 million in research funding from various organisations, including ARC, NHMRC and philanthropy.

For any questions, please contact Rebekah Craggs at rebekah.craggs@mtpconnect.org.au

---